Repository logo
  • English
  • Latviešu
  • Log In
    New user? Click here to register. Have you forgotten your password?
Repository logo
  • Communities & Collections
  • All of DSpace
  • English
  • Latviešu
  • Log In
    New user? Click here to register. Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Andrejevs, N."

Now showing 1 - 3 of 3
Results Per Page
Sort Options
  • No Thumbnail Available
    Item
    Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction : A randomized, placebo-controlled, double-blind study (RUSSLAN)
    (2002-09) Moiseyev, V. S.; Põder, P.; Andrejevs, N.; Ruda, M. Y.; Golikov, A. P.; Lazebnik, L. B.; Kobalava, Z. D.; Lehtonen, L. A.; Laine, T.; Nieminen, Markku S.; Lie, K. I.
    Aims: To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure complicating acute myocardial infarction. Methods and Results: Levosimendan at different doses (0·1-0·4 μg . kg-1 . min-1) or placebo were administered intravenously for 6 h to 504 patients in a randomised, placebo-controlled, double-blind study. The primary end-point was hypotension or myocardial ischaemia of clinical significance adjudicated by an independent Safety Committee. Secondary end-points included risk of death and worsening heart failure, symptoms of heart failure and all-cause mortality. The incidence of ischaemia and/or hypotension was similar in all treatment groups (P=0·319). A higher frequency of ischaemia and/or hypotension was only seen in the highest levosimendan dose group. Levosimendan-treated patients experienced lower risk of death and worsening heart failure than patients receiving placebo, during both the 6h infusion (2·0% vs 5·9%; P=0·033) and over 24 h (4·0% vs 8·8%; P=0·044). Mortality was lower with levosimendan compared with placebo at 14 days (11·7% vs 19·6%; hazard ratio 0·56 [95% CI 0·33-0·951; P=0·031) and the reduction was maintained at the 180-day retrospective follow-up (22·6% vs 31·4%; 0·67 [0·45-1·00], P=0·053). Conclusions: Levosimendan at doses 0·1-0·2 μg . kg-1 . min-1 did not induce hypotension or ischaemia and reduced the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction.
  • No Thumbnail Available
    Item
    Вялотекущий ревмокардит (клиника, биохимия, иммунология)
    (1969) Андреев, Н. А.; Andrejevs, N.
  • No Thumbnail Available
    Item
    Изменение содержания мукоидных веществ в крови при ревматизме
    (1965) Андреев, Н. А.; Andrejevs, N.

DSpace software copyright © 2002-2025 LYRASIS

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback